Oncolys Biopharma (4588.T) traded up 10.79 % during a 24 hours period ending at 10:20 AM Central Europe on Wednesday 28th. One Oncolys Biopharma stock can currently be bought for about JPY 7,900 on popular exchanges. Current supply of Oncolys Biopharma stocks is 26.6 mn. Oncolys Biopharma has a current market capitalization of JPY 185.8 bn and approximately JPY 12.6 bn worth of Oncolys Biopharma was traded on exchanges in the last 24 hours. Since last month end, Oncolys Biopharma has traded 22.46 % up. Simple moving average of last 200 days is at JPY 3,181.84. The highest price of past 52 weeks was recorded at JPY 7,020 on 10/06/2026. 52 weeks low was at JPY 668 on 10/30/2025.

Here is how related stocks have performed in the past 24 hours:

  • Megmilk Snow Brand (2270.T) traded down -0.96 % and now trades at JPY 3,500. Megmilk Snow Brand has a market capitalisation of JPY 219.9 bn. Current price/earnings ratio for Megmilk Snow Brand is 5.78.

  • Artience (4634.T) traded up 0.6 % and now trades at JPY 5,090. Current market capitalisation for Artience is JPY 220.8 bn. Artience has a current price to earnings ratio of 12.92.

  • Starts (8850.T) traded down -1.51 % and now trades at JPY 4,505. Starts has a market capitalisation of JPY 220.4 bn. Starts has a current price to earnings ratio of 8.51.

  • Nishi-nippon Railroad (9031.T) traded up 0.26 % and now trades at JPY 2,845.5. Nishi-nippon Railroad has a market capitalisation of JPY 216.4 bn. Nishi-nippon Railroad has a current price to earnings ratio of 6.36.

  • Dcm (3050.T) traded down -1.54 % and now trades at JPY 1,574. Current market capitalisation for Dcm is JPY 221.8 bn. Current price/earnings ratio for Dcm is 13.11.

About Oncolys Biopharma

Oncolys BioPharma Inc. is a health care biotechnology company based in Tokyo, Japan. The company specializes in conducting research, development, manufacturing, importing, and exporting oncolytic viruses, drugs, and tumor diagnostic agents. Their product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus in Phase I clinical stage for the treatment of esophageal cancer and hepatocellular carcinoma, as well as in Phase II clinical trial for the treatment of melanoma; OBP-801, a histone deacetylase inhibitor in Phase I clinical study for the treatment of solid tumors; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor in Phase II clinical trial for the treatment of HIV infection. Additionally, the company develops TelomeScan (OBP-401 and OBP-1101) for detecting living circulating tumor cells in blood from cancer patients. Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan. Their website is www.oncolys.com , and they are listed on the Tokyo Stock Exchange. The IPO date was December 6, 2013.